HOME >> MEDICINE >> NEWS
Chemist Turns To Self-Assembly To Create New Drugs

Using metal atoms as molecular matchmakers, University of Rochester chemist Benjamin Miller has devised a new way of forming a nearly endless variety of potential drugs, then plucking out the most promising candidates for further study.

Miller's system shifts the burden of the most painstaking drug-development work off the shoulders of technicians and onto tiny molecules, which assemble themselves into countless combinations and then go through a Darwinian process that closely mirrors how nature finds the best compound for a job. If the technology can be expanded for industrial use, it would offer a faster way for chemists to create and screen potential new drugs.

"The approach shows great promise because it's fundamentally more efficient," says Paul Wender, professor of chemistry at Stanford University and an expert in the synthesis of biochemical and medicinal compounds. "The Miller group has clearly shown that this approach makes sense and that it can work. Nature is a huge biodiversity generator, and they've found a way to mimic this process in the laboratory."

Miller's technique relies on atoms of transition metals, such as zinc or cadmium, to build vast libraries of thousands of potential drugs. Just as a skilled host can facilitate socializing between strangers at a cocktail party, these atoms of zinc and cadmium pair up small molecules known as monomers, searching for a fruitful combination. Everyday chemistry then goes to work to "decide" which of the resulting compounds best matches the prospective drug's DNA, RNA, or protein targets, which cause disease. The very best match elbows out all the others to latch onto the target molecule.

"With our technique, we try to find molecules to bind receptors in much the same way nature has for millions of years," says Miller, an assistant professor of chemistry. "We take a receptor we want to target, add many little molecules to it, and see which ones are best at binding the recept
'"/>

Contact: Steve Bradt
sbradt@admin.rochester.edu
716-273-4726
University of Rochester
26-Feb-1998


Page: 1 2 3

Related medicine news :

1. Chemistry and Flavor of Hispanic Foods one-day symposium, March 15
2. Chemists identify immune system mechanism for methamphetamine binges
3. Chemists synthesize molecule that helps body battle cancers, malaria
4. National Chemistry Week celebrates health and wellness in Washington, D.C., area
5. Healthy foods choices highlighted during National Chemistry Week, Oct. 17-23
6. Chemists honor Heroes for biotechnology achievements in health
7. Chemists seek light-activated glue for vascular repair
8. Three Merck chemists win Heroes of Chemistry award for major asthma treatment advance
9. Chemist works to prevent undesirable side effects in synthetic drugs
10. Chemists create synthetic cytochromes
11. Chemists show proteins behave differently inside cells than they do in water solutions

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Chemist Turns Self Assembly Create New Drugs

(Date:6/19/2013)... 2013 Chrysler made news recently when it ... 2.7 million Jeeps. The Jeep models in question are the ... according to the NHTSA are vulnerable to fire and explosion ... models are rear-mounted and have been alleged to catch fire ... Grand Cherokee with 32 rear-end crashes, which resulted in 44 ...
(Date:6/19/2013)... 19, 2013 Amber Roberson with ... Benefits, LLC, Native Care Health, LLC and Medcase, ... Health Underwriters’ (NAHU) new professional development course on ... This continuing education course for agents has been ... receive eleven education credits from the Missouri Department ...
(Date:6/19/2013)... New York, New York (PRWEB) June 19, 2013 ... involving pancreatitis and pancreatic cancer continue to mount in ... the U.S. Food & Drug Administration (FDA) recently held ... other diabetes drugs known as incretin mimetics. According ... may seek additional data from the makers of Januvia ...
(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...
(Date:6/19/2013)... by researchers at The University of Texas MD Anderson ... remarkable promise for the treatment of relapsed or refractory ... findings of the 18-center Phase 2 study were published ... . Previous interim findings were presented in December 2012 ... and Exposition. , Unprecedented results, fewer side ...
Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
(Date:6/19/2013)... 19, 2013 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... New England Journal of Medicine ( NEJM ) ... the investigational oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib ... small lymphocytic lymphoma (SLL). Ibrutinib was shown to be ... SLL, even in patients who were at high-risk due ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance for ... fatigue. The need to urgently address this issue ... Sentinel Event Alert #50 , "Medical device alarm safety in ... between January 2008 and June 2012, there were 98 alarm ... in death (82%) , 13 resulted in permanent loss ...
(Date:6/19/2013)... 2013   Voices Against Brain Cancer (VABC), ... brain cancer, today announced that it has awarded Tocagen ... clinical investigation of Toca 511 & Toca FC in ... cancer (Grade 3 or Grade 4).  Tocagen is a ... cancer, with an initial focus on brain cancer. ...
Breaking Medicine Technology:Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3
Cached News: